Could the AHCA Slow Interest in Genetic Testing?

While it remains uncertain what the Senate will do with the American Health Care Act (AHCA), alarm is spreading about the legislation's implications for the estimated quarter of Americans under the … [Read more...]


Molecular Testing Avoids Significant Pay Cuts in 2017 CLFS

The Revamped G Codes for Definitive Drug Testing (underlined text represents changes from 2016 descriptor) The 2017 CLFS includes modified descriptors of the G codes for differential drug tests so … [Read more...]

Foundation Medicine’s Reimbursement Woes May Signal Broader Industry Challenge

Foundation Medicine (Cambridge, Mass.) candidly reported in quarterly financial filings that reimbursement challenges are stymieing the company's growth. The company's lack of Medicare coverage … [Read more...]

Labs Need to Focus on Providing Data-Driven Value for the System, Lab Institute Experts Say

Laboratory leaders are well aware of the unprecedented number of evolutionary forces exerting pressure on the industry and are heavily focused on regulatory and reimbursement uncertainties. But, … [Read more...]

Shift to Gene Panels to Assess Hereditary Cancer Risk Forges Ahead; Evidence of Clinical Utility, Cost-Effectiveness Emerges

A virtually unlimited number of genes tied to hereditary cancer risk can be simultaneously assessed in commercially available tests given both advances in technology and the Supreme Court’s two-year … [Read more...]

Payment Reform Efforts to Support Cancer Care Coordination, Treatment Planning

The American Society of Clinical Oncology (ASCO) is proposing to profoundly reform payment for cancer care. ASCO's Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More … [Read more...]

Labs Look to Lean Engineering to Transform Operations

With reimbursement challenging revenue in already constrained budgets, laboratories are increasingly looking for financial stability through cost savings achieved with added operational efficiencies. … [Read more...]

Vermillion’s OVA1 Cost-Effective in ID’ing Ovarian Cancer Patients

The OVA1 multivariate index assay (Vermillion; Austin, Texas) is a cost-effective strategy for triaging women with pelvic masses prior to surgery, according to an abstract presented at the American … [Read more...]

Biocept Believes ctDNA, CTCs Both Hold Promise in Future of Liquid Biopsy

This year is poised to be a breakthrough year in the adoption of liquid biopsy technology. Biocept (San Diego) is in position to be at the forefront of this emerging market with a growing menu of … [Read more...]

Sequencing Rapidly Emerging for Epidemiology, Outbreak Control

Much as polymerase chain reaction (PCR) revolutionized microbiology 30 years ago, the application of next-generation sequencing (NGS) to the field of infectious disease will improve surveillance … [Read more...]